empagliflozin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
No detected effect on LDL cholesterol
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The pooled data from five RCTs (377 participants) indicated that empagliflozin did not significantly alter LDL‐C levels (WMD = −8.45 mg/dL, 95% CI: −33.33 to 16.43, p = 0.329; I 2 = 88.5%).”
Quoted verbatim from Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 10 mg/day
- Population
- Adults with MASLD (previously NAFLD or NASH), with or without type 2 diabetes; five RCTs
Effect -8.45 mean difference, 95% CI -33.33 to 16.43
Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.2026PMID:42504019Permalink
Keep reading
- Everything the graph holds on empagliflozin
- Every compound studied against LDL cholesterol
- How to read the evidence strength and the marks
To cite this finding: https://catalystproject.ai/e/01M45EE3XH6A7809SSQSQWEB0K